How should rheumatoid arthritis disease activity be measured today and in the future in clinical care?

Rheumatic Disease Clinics of North America

Volumn 36, Issue 2, 2010, Pages 243-257

  Sokka, Tuulikki ^a  

^a JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

Clinical evaluation; Disease activity; Outcomes; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; LEFLUNOMIDE; METHOTREXATE; PLACEBO;

ARTHRALGIA; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CULTURAL FACTOR; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; GOLD STANDARD; HUMAN; JOINT EXAMINATION; JOINT SWELLING; LABORATORY TEST; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; REFERENCE VALUE; REVIEW; RHEUMATOID ARTHRITIS; SELF REPORT; SEX DIFFERENCE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG MONITORING; HUMANS; REFERENCE STANDARDS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77953235192     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2010.02.007     Document Type: Review

References (119)

1. Smith T. Questions on clinical trials. Br Med J 1983, 287:569. [editorial].
2. Luukkainen R., Kajander A., Isomäki H. Treatment of rheumatoid arthritis. Br Med J 1978, 2:1501. [letter].
3. Möttönen T., Hannonen P., Leirisalo-Repo M., et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999, 353:1568-1573.
4. Makinen H., Kautiainen H., Hannonen P., et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007, 34(2):316-321.
5. Grigor C., Capell H., Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364:263-269.
6. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005, 52:3381-3390.
7. Verstappen S.M., Jacobs J.W., van der Veen M.J., et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007, 66(11):1443-1449.
8. Hetland M.L., Stengaard-Pedersen K., Junker P., et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008, 67:815-822.
9. Fransen J., Moens H.B., Speyer I., et al. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised contolled trial. Ann Rheum Dis 2005, 64:1294-1298.
10. Sokka T., Kautiainen H., Häkkinen K., et al. Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol 2004, 31:1073-1082.
11. Pincus T., Sokka T., Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005, 52:1009-1019.
12. Uhlig T., Heiberg T., Mowinckel P., et al. Rheumatoid arthritis is milder in the new millennium: health status in patients with rheumatoid arthritis 1994-2004. Ann Rheum Dis 2008, 67(12):1710-1715.
13. Pincus T. The DAS is the most specific measure, but a patient questionnaire is the most informative measure to assess rheumatoid arthritis. J Rheumatol 2006, 33:834-837.
14. Cooperating Clinics Committee of the American Rheumatism Association A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965, 8:302-335.
15. Ritchie D.M., Boyle J.A., McInnes J.M., et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968, 37:393-406. New Series.
16. American Rheumatism Association Dictionary of the rheumatic diseases, vol. I: signs and symptoms 1982, Contact Associates International, New York.
17. Decker J.L. American Rheumatism Association nomenclature and classification of arthritis and rheumatism. Arthritis Rheum 1983, 26:1029-1032.
18. Bombardier C., Tugwell P., Sinclair A., et al. Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumatol 1982, 9:798-801.
19. Wolfe F., Pincus T., Thompson A.K., et al. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Arthritis Care Res 2003, 49(1):59-63.
20. Boers M., Tugwell P., Felson D.T., et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994, 21(Suppl 41):86-89.
21. Felson D.T., Anderson J.J., Boers M., et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993, 36:729-740.
22. American College of Rheumatology Committee to Reevaluate Improvement Criteria A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum 2007, 57(2):193-202.
23. Pincus T. Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis 2008, 66(3):216-223.
24. Sokka T., Pincus T. Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations. Rheum Dis Clin North Am 2009, 35(4):713. vi.
25. Lansbury J., Baier H.N., McCracken S. Statistical study of variation in systemic and articular indexes. Arthritis Rheum 1962, 5:445-456.
26. Eberl D.R., Fasching V., Rahlfs V., et al. Repeatability and objectivity of various measurements in rheumatoid arthritis: a comparative study. Arthritis Rheum 1976, 19:1278-1286.
27. Hanson M.T., Keiding S., Lauritzen S.L., et al. Clinical assessment of disease activity in rheumatoid arthritis. Scand J Rheumatol 1979, 8:101-105.
28. Hart L.E., Tugwell P., Buchanan W.W., et al. Grading of tenderness as a source of interrater error in the Ritchie articular index. J Rheumatol 1985, 12:716-717.
29. Thompson P.W., Kirwan J.R. Observer variation and the Ritchie articular index. J Rheumatol 1986, 13:836-837.
30. Lewis P.A., O'Sullivan M.M., Rumfeld W.R., et al. Significant changes in Ritchie scores. Br J Rheumatol 1988, 27:32-36.
31. Klinkhoff A.V., Bellamy N., Bombardier C., et al. An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol 1988, 15:492-494.
32. Thompson P.W., Kirwan J.R., Currey H.L.F. A comparison of the ability of 28 articular indices to detect an induced flare of joint inflammation in rheumatoid arthritis. Br J Rheumatol 1988, 27:375-380.
33. Fuchs H.A., Brooks R.H., Callahan L.F., et al. A simplified twenty-eight joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989, 32:531-537.
34. Thompson P.W., Hart L.E., Goldsmith C.H., et al. Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. J Rheumatol 1991, 18:661-665.
35. Bellamy N., Anastassiades T.P., Buchanan W.W., et al. Rheumatoid arthritis antirheumatic drug trials. 1. Effects of standardization procedures on observer dependent outcome measures. J Rheumatol 1991, 18:1893-1900.
36. Scott D.L., Choy E.H., Greeves A., et al. Standardising joint assessment in rheumatoid arthritis. Clin Rheumatol 1996, 15:579-582.
37. Lassere M.N., van der Heijde D., Johnson K.R., et al. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol 2001, 28(4):892-903.
38. Tugwell P., Wells G., Strand V., et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000, 43(3):506-514.
39. Strand V., Cohen S., Crawford B., et al. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology 2004, 43:640-647.
40. Wakefield R.J., Green M.J., Marzo-Ortega H., et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis 2004, 63:382-385.
41. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand 1940, 17:172-178.
42. Rose H.M., Ragan C., Pearce E., et al. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med 1948, 68:1-6.
43. Abelson B., Rupel A., Pincus T. Limitations of a biomedical model to explain socioeconomic disparities in mortality of rheumatic and cardiovascular diseases. Clin Exp Rheumatol 2008, 26(5 Suppl 51):S25-S34.
44. Sokka T., Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003, 30(6):1138-1146.
45. Pinals R.S., Masi A.T., Larsen R.A., et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24:1308-1315.
46. Wolfe F., Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol 1994, 21:1227-1237.
47. Sokka T., Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 2009, 36(7):1387-1390.
48. Abelson B., Sokka T., Pincus T. Declines in erythrocyte sedimentation rates in patients with rheumatoid arthritis over the second half of the 20th century. J Rheumatol 2009, 36(8):1596-1599.
49. Wolfe F., Pincus T. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. J Rheumatol 2001, 28(8):1817-1824.
50. Isomäki H.A., Hakulinen T., Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978, 31:691-696.
51. Miller A., Green M., Robinson D. Short rule for calculating normal erythrocyte sedimentation rate. Br Med J 1983, 286:266.
52. Sokka T., Hetland M.L., Makinen H., et al. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 2008, 58(9):2642-2651.
53. Fries J.F., Spitz P., Kraines R.G., et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145.
54. Pincus T., Summey J.A., Soraci S.A., et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum 1983, 26:1346-1353.
55. Pincus T., Swearingen C., Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthritis Rheum 1999, 42:2220-2230.
56. Pincus T., Sokka T., Kautiainen H. Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. J Rheumatol 2005, 32:1432-1439.
57. Pincus T., Yazici Y., Bergman M. Development of a multi-dimensional health assessment questionnaire (MDHAQ) for the infrastructure of standard clinical care. Clin Exp Rheumatol 2005, 23:S19-S28.
58. Pincus T., Callahan L.F., Sale W.G., et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984, 27:864-872.
59. Wolfe F., Cathey M.A. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991, 18:1298-1306.
60. Callahan L.F., Bloch D.A., Pincus T. Identification of work disability in rheumatoid arthritis: physical, radiographic and laboratory variables do not add explanatory power to demographic and functional variables. J Clin Epidemiol 1992, 45:127-138.
61. Wolfe F., Hawley D.J. The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998, 25:2108-2117.
62. Sokka T., Kautiainen H., Möttönen T., et al. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999, 26:1681-1685.
63. Lubeck D.P., Spitz P.W., Fries J.F., et al. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986, 29:488-493.
64. Wolfe F., Zwillich S.H. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998, 41:1072-1082.
65. Wolfe F., Kleinheksel S.M., Cathey M.A., et al. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988, 15:1480-1488.
66. Leigh J.P., Fries J.F. Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol 1991, 18:1307-1312.
67. Pincus T., Brooks R.H., Callahan L.F. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994, 120:26-34.
68. Callahan L.F., Cordray D.S., Wells G., et al. Formal education and five-year mortality in rheumatoid arthritis: mediation by helplessness scale scores. Arthritis Care Res 1996, 9:463-472.
69. Callahan L.F., Pincus T., Huston J.W., et al. Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997, 10:381-394.
70. Söderlin M.K., Nieminen P., Hakala M. Functional status predicts mortality in a community based rheumatoid arthritis population. J Rheumatol 1998, 25:1895-1899.
71. Sokka T., Hakkinen A., Krishnan E., et al. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004, 63:494-497.
72. Sokka T., Hakkinen A. Poor physical fitness and performance as predictors of mortality in normal populations and patients with rheumatic and other diseases. Clin Exp Rheumatol 2008, 26(5 Suppl 5):14-20.
73. Barsky A.J., Peekna H.M., Borus J.F. Somatic symptom reporting in women and men. J Gen Intern Med 2001, 16(4):266-275.
74. Keogh E., Herdenfeldt M. Gender, coping and the perception of pain. Pain 2002, 97(3):195-201.
75. Loge J.H., Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med 1998, 26(4):250-258.
76. Bowling A., Bond M., Jenkinson C., et al. Short Form 36 (SF-36) Health Survey questionnaire: which normative data should be used? Comparisons between the norms provided by the Omnibus Survey in Britain, the Health Survey for England and the Oxford Healthy Life Survey. J Public Health Med 1999, 21(3):255-270.
77. Katz P.P., Criswell L.A. Differences in symptom reports between men and women with rheumatoid arthritis. Arthritis Care Res 1996, 9(6):441-448.
78. Sherrer Y.S., Bloch D.A., Mitchell D.M., et al. Disability in rheumatoid arthritis: comparison of prognostic factors across three populations. J Rheumatol 1987, 14:705-709.
79. Thompson P.W., Pegley F.S. A comparison of disability measured by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female rheumatoid outpatients. Br J Rheumatol 1991, 30(4):298-300.
80. McKenna F., Tracey A., Hayes J. Assessment of disability in male and female rheumatoid patients. Br J Rheumatol 1991, 30(6):477.
81. Sokka T., Krishnan E., Häkkinen A., et al. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003, 48(1):59-63.
82. Sokka T., Toloza S., Cutolo M., et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study. Arthritis Res Ther 2009, 11(1):R7.
83. Hakkinen A., Kautiainen H., Hannonen P., et al. Muscle strength, pain, and disease activity explain individual subdimensions of the health assessment questionnaire disability index, especially in women with rheumatoid arthritis. Ann Rheum Dis 2006, 65(1):30-34.
84. Hallert E., Thyberg I., Hass U., et al. Comparison between women and men with recent onset rheumatoid arthritis of disease activity and functional disability over two years (the TIRA project). Ann Rheum Dis 2003, 62:667-670.
85. Krishnan E., Sokka T., Hakkinen A., et al. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004, 50:953-960.
86. Yazici Y., Kautiainen H., Sokka T. Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data. J Rheumatol 2007, 34(2):311-315.
87. Felson D.T., Anderson J.J., Boers M., et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735.
88. van der Heijde D.M., van't Hof M.A., van Riel P.L., et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990, 49:916-920.
89. van der Heijde D.M., van't Hof M., van Riel P.L., et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993, 20:579-581.
90. Prevoo M.L., van't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
91. Smolen J.S., Breedveld F.C., Schiff M.H., et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003, 42:244-257.
92. Aletaha D., Nell V.P., Stamm T., et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005, 7:R796-R806.
93. Makinen H., Kautiainen H., Hannonen P., et al. A new disease activity index for rheumatoid arthritis: Mean Overall Index for Rheumatoid Arthritis (MOI-RA). J Rheumatol 2008, 35(8):1522-1527.
94. Kristensen L.E., Saxne T., Geborek P., et al. A new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006, 54(2):600-606.
95. Pincus T., Bergman M.J., Yazici Y., et al. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 2008, 47(3):345-349.
96. Pincus T., Swearingen C.J., Bergman M., et al. RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to DAS and CDAI categories. J Rheumatol 2008, 35:2136-2147.
97. Pincus T., Strand V., Koch G., et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003, 48(3):625-630.
98. Pincus T., Amara I., Koch G.G. Continuous indices of Core Data Set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum 2005, 52:1031-1036.
99. Pincus T., Chung C., Segurado O.G., et al. An index of patient self-reported outcomes (PRO Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 2006, 33:2146-2152.
100. Sokka T. Long-term outcomes of rheumatoid arthritis. Curr Opin Rheumatol 2009, 21(3):284-290.
101. Makinen H., Hannonen P., Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomized clinical trials for the rate of remission. Clin Exp Rheumatol 2006, 24(S43):S22-S28.
102. Forslind K., Hafstrom I., Ahlmen M., et al. Sex: a major predictor of remission in early rheumatoid arthritis?. Ann Rheum Dis 2007, 66(1):46-52.
103. Mancarella L., Bobbio-Pallavicini F., Ceccarelli F., et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007, 34(8):1670-1673.
104. Hyrich K.L., Watson K.D., Silman A.J., et al. British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006, 45(12):1558-1565.
105. Yamanaka H., Tanaka Y., Sekiguchi N., et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 2007, 17(1):28-32.
106. Kvien T.K., Uhlig T., Odegard S., et al. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 2006, 1069:212-222.
107. Pincus T., Sokka T., Kavanaugh A. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for " near remission" of DAS or single measures. Clin Exp Rheumatol 2004, 22(Suppl 35):S50-S56.
108. Puolakka K., Kautiainen H., Möttönen T., et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005, 52(1):36-41.
109. Pincus T., Brooks R.H., Callahan L.F. A proposed standard protocol to evaluate rheumatoid arthritis (SPERA) that includes measures of inflammatory activity, joint damage, and longterm outcomes. J Rheumatol 1999, 26:473-480.
110. Pincus T., Sokka T. A three-page Standard Protocol to Evaluate Rheumatoid Arthritis (SPERA) for efficient capture of essential data from patients and health professionals in standard clinical care and clinical research. Best Pract Res Clin Rheumatol 2007, 21(4):677-685.
111. Fuchs H.A., Kaye J.J., Callahan L.F., et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989, 16:585-591.
112. Pincus T., Callahan L.F., Brooks R.H., et al. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med 1989, 110:259-266.
113. Sokka T., Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003, 48(2):313-318.
114. Sokka T., Kautiainen H., Toloza S., et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007, 66:1491-1496.
115. Sokka T., Kautiainen H., Pincus T., et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009, 68:1666-1672.
116. Khan N.A., Yazici Y., Calvo-Alen J., et al. Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. J Rheumatol 2009, 36:2435-2442.
117. Naranjo A., Sokka T., Descalzo M., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008, 10:R30.
118. Sokka T., Pincus T. Quantitative joint assessment in rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:S58-S62.
119. Wolfe F., Lassere M., van der Heijde D., et al. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. Omeract IV: outcome measures in rheumatology. Cancun, Mexico, April 16-20, 1998. J Rheumatol 1999, 26:484-489.